Adam heads Business Operations for Galvani Bioelectronics. In this capacity he leads a variety of functions including business development and transactions, alliance management, procurement, IT, market insights, strategy, grants, communications, administration, and facilities.
Prior to the formation of Galvani, Adam led business development activities for the Bioelectronics R&D unit of GlaxoSmithKline (GSK). He joined GSK in 2010, working within R&D strategy for the Pharmaceutical R&D organization. Prior joining GSK, Adam worked in the healthcare consulting practice of McKinsey & Company and in finance within the semiconductor manufacturing division of the Intel Corporation.
He holds a Ph.D. in Cellular and Molecular Biology, an MBA specializing in Finance & Entrepreneurship, and a B.S. in Engineering Science and Mechanics, concentrating in Biomedical Engineering.
Firat brings pioneering our miniaturised Bioelectronic devices to reality. Working in Neuromodulation Devices, he joined GSK Bioelectronics in 2015 after spending 13 years at imec, Europe’s largest independent research centre in microelectronics and nanoelectronics. He has developed devices and technologies for medical-grade wearable and implantable biomedical devices, including wireless cardiac monitoring patches, wearable EEG monitoring headsets and implantable neural probes for high density recording. Firat was also involved in the creation of a San Francisco-based wearable healthcare start-up, Bloom Technologies.
With a Ph.D. from KU Leuven in Belgium, Firat has authored more than 100 peer-reviewed publications along with 20 patents, including a book on low-power biomedical microsystems. He has served on the technical program committees of European Solid State Circuits Conf (ESSCIRC), International Solid State Circuits Conf (ISSCC), and Biomedical Circuits and Systems Conf (BioCAS) and remains Associate Editor for IEEE Trans. of Biomedical Circuits and Systems.
Gwyn leads our legal and intellectual property activities for Galvani Bioelectronics. Since joining GSK in 2006, Gwyn has had an increasingly globally diverse role – providing intellectual property counsel in developing patent portfolios across therapeutic areas, and providing legal and transactional counsel. She advised the business in a complex and rapidly developing environment of collaborative R&D, conducted in public-private partnerships, with non-profit and supranational funding. Gwyn also provided IP counsel for Vaccines transactions, and has supported several patent litigations relating to vaccine products.
Gwyn previously worked in private legal practice, developing and executing patent strategies in diverse technology areas for start-up companies in the biotechnology space – and for academic and government institutions.
Gwyn earned a PhD in Genetics from Yale University and performed postdoctoral research in immunology before transitioning into law. She has a JD degree from University of California, Berkeley (Boalt Hall) and is a member of the US Patent Bar.
Kathy Jo Fahey
Kathy leads the Regulatory, Quality and Clinical Operations activities for Galvani Bioelectronics. She joined the team in 2017.
Kathy has more than 25 years of medical device experience in quality, regulatory, and clinical trial design for class I, II, and III medical devices, including numerous worldwide approvals. Prior to Galvani, she led the Quality, Regulatory and Clinical functions at Nuvectra and Regulatory and Clinical functions at Respicardia. She also has more than 20 years at Medtronic, where she held multiple leadership roles in the cardiac rhythm management, structural heart, and neurological businesses.
Kris is president of Galvani Bioelectronics, being overall responsible for the company’s path to and delivery of bioelectronic medicines to patients. Before his appointment to lead Galvani Bioelectronics, he was founding VP and head of Bioelectronics R&D at GSK, which he launched in 2013. There he managed the unit’s extensive research towards establishing the treatment potential, disease reach and technology requirements for bioelectronic medicines, working together with a network of research partners across academia and industry.
During his time at GSK he also headed up the R&D Strategy Group and the Protein Degradation Discovery Performance Unit.
Kris obtained his PhD in Molecular Biology at University of Cambridge, following an MSc in Chemical Engineering at Lund University, Sweden. Before joining GSK in 2009, he worked as a management consultant at McKinsey & Co
René Van Der Merwe
Joining Galvani in February 2021, René has over 18 years’ clinical development experience in small molecule and biotherapeutics development, working with major pharmaceutical companies and contract research organisations across a number of auto-immune, respiratory and neurology indications. Prior to joining Galvani, René held positions of VP Respiratory at Medimmune and SVP Global Clinical Development at DBV Technologies.
René has a MBChB from the Freestate University, South Africa and a MSc in Clinical Pharmacology from the University of Surrey.
Rhiannon is Galvani’s Head of HR and a member of the company’s management team. Before her appointment in Galvani Bioelectronics, Rhiannon held multiple roles within GSK’s HR function, ranging from HR leadership at one of GSK’s pharmaceutical manufacturing sites, to partnering with a number of GSK’s corporate support functions.
Rhiannon has a Bachelor’s degree in Management, a MSc in Human Resource Management & Organisational Analysis and is CIPD qualified.
Suzanne is Head of Finance for Galvani Bioelectronics. She joined the team in January 2019.
Suzanne has over 15 years’ experience within GSK during which time she has held a number of different positions across the organisation including in Corporate Finance, Commercial Finance Partner, UK Pharma and Financial Controller, Norway Pharma based in Oslo. Prior to Galvani, Suzanne was Finance Director, Respiratory R&D providing financial leadership to the early stage Discovery Performance Units (DPUs).
Suzanne has a BSc in Mathematics from the University of Exeter. Prior to joining GSK she trained as a Chartered Accountant at KPMG in London.
Board of directors
Amy Altshul is GSK’s Senior Vice President for Legal supporting R&D and the Global Commercial Franchise organisations. In her current role, Amy is accountable for all legal matters relating to R&D across Vaccines and Pharma as well as the global commercial organisations for Oncology and Specialty and Primary Care
Amy joined GSK in 2009 in the Business Development transactions legal team and during more than ten years with the company she has led the legal support across areas such as Rare Diseases and Cell & Gene Therapy. She holds a Bachelor of Science degrees in biology and chemistry and has completed Masters coursework in medicinal chemistry.
Prior to law school, Amy was a researcher at the National Cancer Institute conducting studies in secondary leukemia. She spent several years in private legal practice in New York as a corporate transactional lawyer, before going in-house at Wyeth Pharma, then Pfizer, Inc., before joining GSK. Amy is also a licensed patent attorney. She is passionate about science and the potential of new technologies to enhance the quality of life of patients.
Brad Hirsch, MD, was the founder and CEO of SignalPath, a clinical trials technology company that was acquired by Verily in September of 2021. He subsequently joined the leadership of Verily’s Clinical Studies Platform. Under Brad’s leadership, SignalPath was widely adopted by leading research sites and sponsors to drive efficiency and effectiveness across their clinical research portfolio.
Prior to SignalPath, Brad held roles at Flatiron Health, a technology company focused on the use of clinical data for research, and was on the faculty at Duke University. He is a medical oncologist and has been a principal investigator on multiple trials, ensuring that he has a deep understanding of the needs of clinical sites and sponsors. Brad received his BA from the University of Pennsylvania, his MD from UT Southwestern and his MBA from Duke University’s Fuqua School of Business.
Chris Corsico is the chairman of the Galvani Board of Directors. Chris joined GSK as the Global Head of Development in 2019. The Development organization is responsible for supporting pipeline clinical development from phase II through approval and the pharmaceutical marketed portfolio from approval through end of the life cycle.
Prior to joining GSK, Chris worked at Boehringer Ingelheim (BI) for over 20 years, his last several years as the Global Head of Medicine and Chief Medical Officer. Prior to that, Chris worked in BI’s US organization in various roles including Head of Regional Pharmacovigilance, Head of US Regulatory Affairs and Medical Director, North America.
Chris was a Howard Hughes-National Institutes of Health Research Scholar where he studied mammalian cell regulation and growth inhibition in the laboratory of Dr. Bruce Howard at the National Cancer Institute. Chris received his medical degree from the Cornell University College of Medicine in New York City and his MPH from the School of Public Health at Yale University. Chris trained in Internal Medicine at the Johns Hopkins University School of Medicine. He practiced Internal Medicine at the Johns Hopkins Medical Services Corporation and was an Assistant Professor of Internal Medicine at the Dartmouth Hitchcock Medical Center and Dartmouth Medical School prior to joining industry
Jordi leads Verily’s medical devices business, combining hardware with software and machine learning to create differentiated product solutions that support Verily’s research and health platforms, as well as external partnerships and joint ventures. Areas of interest include wearable monitoring sensors, diagnostics, surgical robotics, bioelectronics, ophthalmology and drug delivery devices. Jordi has more than 20 years of experience in the Medical Devices industry including a 12-year tenure at Boston Scientific before joining Verily. Jordi has authored more than 60 distinct patent families with 200+ granted patents worldwide. He holds a BS degree in Physics from the Universitat Autònoma de Barcelona and BS, MS and PhD degrees in Electrical Engineering from the National Center for Microelectronics of Spain at the Universitat Autònoma de Barcelona.
Kaigham J. (Ken) Gabriel is currently Chief Operating Officer of Wellcome Leap, a nonprofit spin out of Wellcome Trust with a mission to accelerate human health discovery and innovation by building bold and unconventional programmes and funding them at scale.
Ken was most recently president and Chief Executive Officer of The Charles Stark Draper Laboratory, an independent not-for-profit research institution that develops innovative technology solutions in the fields of national security, space, biomedical systems and energy. Prior to that, Ken co-founded and served as Deputy Director of the Advanced Technology and Projects (ATAP) group at Google from 2012 to 2014 and as Corporate Vice President at Google/Motorola Mobility. From 2009 to 2012, he was the Deputy Director, and then acting director, of the Defense Advanced Research Projects Agency (DARPA). Between 2002 and 2009, Ken was the Co-Founder, Chairman and Chief Technology Officer of Akustica, a fabless semiconductor company that commercialized Micro Electro Mechanical Systems audio devices and sensors.
Ken holds SM and ScD degrees in Electrical Engineering and Computer Science from the Massachusetts Institute of Technology
Subesh Williams is Senior Vice President, Global Corporate Development at GSK, a role he was appointed to in September 2013. In his current role, Subesh is responsible for M&A and Business Development across GSK’s commercial businesses and has been involved in executing a number of transactions, including the creation of ViiV Healthcare (a HIV JV with Pfizer and Shionogi) and the three – way deal with Novartis which involved the acquisition of Novartis’ vaccines business, the creation of a JV in Consumer Healthcare and the sale of GSK’s oncology business. From 2009- 2013, Subesh was Chief Financial Officer of ViiV Healthcare, with responsibility for Finance, Business Development, IT and Supply. Subesh joined GSK in 1994 and has had roles of increasing responsibility in Finance and Corporate Development. Subesh is a chartered accountant and, prior to joining GSK, was a manager at PwC.
William J. Marks, Jr., MD, MS-HCM is Head of Clinical Science at Verily, where he is responsible for the team of physicians, other clinicians, and scientists who provide clinical and scientific expertise across the company. Dr. Marks received an Honors Bachelor of Science degree in Biology from Marquette University and his Medical Degree from the Johns Hopkins University School of Medicine. He completed his neurology residency and fellowship at the University of California, San Francisco (UCSF). Dr. Marks also holds a Master of Science in Healthcare Management degree from the Harvard School of Public Health. Before joining Verily in 2016, he was Professor of Neurology at UCSF. He is now Adjunct Clinical Professor of Neurology & Neurological Sciences at Stanford University School of Medicine.
Galvani Bioelectronics Team
Akin is the lead mechanical design engineer for implantable devices and test systems in the neural interfaces team. He also works closely with translational sciences and surgical teams to identify and implement design requirements for neural interface devices.
Akin holds a B.Sc. in Mechanical Engineering from Coventry university and a master’s in automotive engineering from the university of Brighton.
Akin started his career working on high-speed air movement systems for Torin-Sifan before joining Dyson as a mechanical design engineer owning motors and drives design for several mass-produced environmental care projects
Alice is responsible for intellectual property activities for Galvani Bioelectronics. Alice joined GSK in 2004 and has developed worldwide patent strategies for internationally-based research teams, managed worldwide outside counsel in patent prosecution and litigation matters and has advised R&D and Business Development decision makers on patentability, freedom-to-operate issues, in-licensing opportunities and regulations governing development of NIH funded technology.
She has a BS in Biological Sciences, a PhD in Microbiology (Immunology focus) and postdoctoral experience in HIV and Immunology. She is a member of the North Carolina State Bar and a patent attorney registered to practice before the U.S. Patent and Trademark Office.
Acting as the primary interface between Galvani’s Business and IT Operations organisations, Andrew leverages his expertise to ensure Galvani’s business systems are fit for purpose and running smoothly. Through solution architecting, vendor selection and assessment, implementation and ongoing technical engineering and support, Andrew maintains a detailed understanding of the IT platforms supporting business processes and ensures they are optimally deployed.
Billie-Jo Page, MHRM (HR) is a Senior Team Administrator with over 10 years experience working in HR Recruitment and Executive support. Billie-Jo works closely with Galvani’s Administrator team to provide support to Galvani Bioelectronics.
Prior to joining Galvani in 2017 she worked for GSK and Cisco Systems in Global HR roles while also handling multiple projects, energy/reward and resilience initiatives, and HR support for employees, vendors and stakeholders on a global level.
Caroline Dundridge is the Executive Assistant to Kris Famm and provides support to the Galvani Management Team.
Prior to joining Galvani, she worked at Citigroup Investment Bank and PCS Legal.
Christopher Lai, MD, MBA is a Director in Business Development and Project Management for Galvani Bioelectronics. His main role is to facilitate Galvani Bioelectronics transactions and support the development of our assets to clinical development.
Prior to Galvani Bioelectronics, Christopher was with GSK for 3 years, working in Worldwide Business Development and R&D Strategy Development. Prior to this role, he was in U.S. Respiratory Finance, supporting GSK’s respiratory launches of Anoro, Breo and Nucala.
Before GSK, Christopher was an emergency physician who practiced at several institutions such as Kaiser, Sutter and Duke. He continues to practice at the Durham VA ER. He obtained his business degree at Duke University’s Fuqua School of Business in 2013, his medical degree at The Ohio State University College of Medicine in 2002 and trained in Emergency Medicine at the University of Pittsburgh in 2005. Prior to medical school, he spent nearly 2 sleepless years at Citigroup in investment banking.
Daniel is a founding member of Galvani Bioelectronics and leads the Translational Research team within. The team is based in the UK with dedicated onsite electrophysiology laboratories, as well as managing academic and CRO collaborators externally.
Translational research for Galvani focuses on preclinical-to-clinical studies of autonomic nervous system neuromodulation, and the ability to modulate organ physiology and treat disease across an indication pipeline. Research explores the fundamentals of nerve physiology, translational biology, and pathophysiology, while discovering and optimising ways of interaction with disparate visceral neuroanatomy. This involves the pursuit of in silico, ex vivo, and in vivo electrophysiology methods to determine the efficacy and safety profiles of Galvani therapies, with the goal of delivering clinical therapy.
Prior to industry research at GSK and Galvani, Daniel studied Neuroscience at the University of London; Queen Mary (PhD – 2009), and the University of Cambridge (Post Doctorate – 2009-2013). Research from his academic career focused on understanding the dynamics of the peripheral nervous system, developing pre-clinical in vivo neurosurgical models, and novel neuroprosthetic design and application. Daniel is the Home Office License Holder and Risk and Ethics owner for in vivo research in Galvani, and is author to over 50 scientific publications and patent applications.
David leads the way in our commercial activities. As Therapeutic Vision and Commercial Strategy Director for Galvani Bioelectronics, his work includes acquiring customer and market insights, delivering early commercial input into therapies of interest – and exploring future commercial models.
Before joining the Galvani Bioelectronics team, David’s previous roles spanned commercial planning and marketing at GSK – including payer marketing, new product commercial analysis and global strategic marketing – across an array of therapies areas.
With an undergraduate degree from Boston College and MBA from Cornell University, he brings a wealth of experience from the healthcare industry, from a global marketing oncology role at Centocor/Johnson & Johnson and as a consultant for the healthcare strategy firm, The Wilkerson Group.
Following formal schooling, which included a B.S.E. degree from Duke University and a Ph.D. degree from Case Western Reserve University in Biomedical Engineering, David performed pre-clinical and clinical research on Class II and III medical devices for over 20 years, in both US and European geographies. His study experiences ranged from unique Phase I studies (where scientific concepts were translated into first human experience), to Phase III pivotal trials. The therapeutic targets for these studies included cardiac arrhythmias, heart failure, sleep apnea, intractable pain, and traumatic injuries.
David joined Galvani in 2017, and leads the Clinical Operations program that works with clinical sites to conduct studies of Galvani’s bioelectric medicine systems.
David works within the Translational Sciences group to perform and manage in-house and collaborative electrophysiological studies in small and large animal models and human tissue, aimed at developing and refining clinically-relevant stimulation parameters. David has a long-standing interest in neural interfacing; during his PhD he worked to develop high-density neuronal recordings with applications for the treatment of epilepsy. Prior to Galvani Bioelectronics, David has over 20 years of experience in Neuroscience, the last 15 of which has been in Psychiatric Drug Discovery within major international pharmaceutical companies.
Dean leads the IT department within Galvani Bioelectronics and is accountable for Galvani’s global business systems and technology infrastructure.
Prior to joining Galvani, Dean acted as a Functional Consultant at GSK, where he was responsible for deploying GSK’s Global SAP solution to a number of GSK’s manufacturing facilities around the world. Dean obtained his MPhil in Engineering from the University of Cambridge and his BSc Engineering in Mechatronics from the University of Cape Town.
Eric is board certified General and Vascular surgery with over 25 years of clinical experience in these areas. He is an adjunct professor of surgery at the University of Minnesota where he is involved in training for medical students, residents and practicing clinicians and is involved in clinical research activities.
During the past 18 years he has also worked with biomedical device companies developing therapies to treat cardiovascular and pulmonary diseases. In these efforts he has worked in initial proof of concept studies; with R&D teams to develop initial implantable systems and to improve their usability; and with Clinical and Regulatory staff in clinical protocol development and establishing clinical events committees for clinical trials.
Eric worked with Galvani Bioelectronics since its inception working to study the anatomy at proposed interface sites, develop surgical techniques for humans and perform risk assessments and risk mitigation strategies for the surgical procedures developed to implant the neuromodulation systems.
Faisal Zaidi brings multi-disciplinary “concept-to-product/bench-to-bedside” expertise in the development of neuromodulation therapies.
Faisal has a long-standing interest in developing de novo bioelectronic implants as an alternative to drug therapies. Prior to joining Galvani Bioelectronics in 2017, he spent 10+ years in working with biomedical industries developing Class III electroceutical devices to treat neurological disorders.
Faisal is a widely published neuroscientist with a PhD from National Center for Biological Sciences (Tata Institute of Fundamental Research) and a HHMI Post-Doctoral Fellow at Department of Neurosciences, University of California, San Diego. He has MS in Biotechnology and BS in Biochemistry. He authored numerous peer-reviewed publications, IPs, abstracts, reviewed book chapters & science articles, taught medical courses and chaired meeting sessions.
Grace is an Investigator (Clinical Translation) within the Translational Medicine group at Galvani Bioelectronics. Her role centres around the design, execution and interpretation of high-dimensional flow cytometry experiments to support Galvani’s Indication Expansion Programme in the identification of novel disease targets for neuromodulatory therapy. Data from this work will provide comprehensive information about the immune phenotype of relevant disease models and identify biomarkers for monitoring disease progression and efficacy of neuromodulation. In parallel, training in clinical development and clinical operations is being undertaken to provide support for Galvani’s clinical work.
Hanna is the Quality Manager for Galvani Bioelectronics. She is responsible for implementation and maintenance of the quality system, and for ensuring quality and regulatory compliance across the organization.
Prior to joining Galvani, she was responsible for the quality and regulatory functions of multiple medical device start-ups and worked closely with R&D and clinical teams to usher devices from concept phase to commercialization. She has a Bachelor of Science in Biomedical Computation from Stanford University.
Hugh is a Programme Manager within the neural interface development team at Galvani Bioelectronics. In this role, he is responsible for developing novel, implantable neurostimulation leads.
Hugh has worked in project leadership roles in the medical device industry for over five years. Prior to joining Galvani, he was a Project Manager at Cambridge Consultants, where he built on his prior experience in the pharmaceutical industry to lead the design and development of novel drug delivery systems and surgical technologies.
Hugh is a Chartered Engineer and holds a Master of Engineering in Mechanical Engineering with Bioengineering from Newcastle University, as well as post graduate qualifications in Industrial Project Management from the University of Birmingham.
Isha is a Senior Investigator with the Translational and Engineering group in Galvani Bioelectronics. Her role is to manage in-house and collaborative electrophysiology and computational modelling studies aimed at investigating and refining clinically relevant dose for multiple disease indications. She works with Clinical team as a Field Clinical Engineer to implement & investigate therapies in the clinic. She also manages and drives academic and industrial collaborations such as CRACK-IT focussed on driving research into novel and future platforms for early disease indications.
Isha is a PhD graduate in Electronics and Electrical Engineering from the University of Southampton (2018). Work from her PhD focussed on exploiting emerging nanoelectronic memristive devices for the application of neural signal processing, with wider application in Internet-of-Things computing. Her scientific work is described in several patents and over twenty peer reviewed publications.
Jane is a Director in the Business Operations team. Her role is to support Galvani’s portfolio of external collaborations by facilitating transactions for a wide range of contractual agreements with academic institutions, hospitals and companies.
Prior to joining Galvani she has worked at GSK for over 30 years, initially in natural products and biological screening research and subsequently in Business Development and Academic Liaison. She has a BSc in Biological Sciences and Statistics and a PhD in plant physiology.
Jason investigates the interaction between biology and technology. Using electrophysiology and integrative biology, he works to understand the stimulation parameters and device configurations required to modulate peripheral organ function.
Prior to joining Galvani Bioelectronics, Jason spent seven years in small molecule drug discovery, studying mechanisms of sensory processing and neuroregeneration.
Jason holds a PhD in Neuroscience and a BSc in Cell Biology and Physiology. During his academic research he discovered new interactions between reproductive endocrinology, sensory processing and behaviour.
Jerry is an in vitro/ex vivo Investigator within Disease Biology primarily supporting the respiratory portfolio projects. He has a keen interest in novel mechanisms and interfaces to achieve fiber selective modulation of peripheral nerves to treat disease. In this role, Jerry also works closely with the Target Discovery and Neuronal Modulation Devices groups to help identify user requirements and functionality testing of neuronal interfaces.
Prior to joining Galvani Bioelectronics, Jerry worked for 10+ years in GSK’s Respiratory Therapeutic Area Unit and Neuronal Targets Discovery Performance Unit supporting lead optimisation of various chemical series targeting GPCRs and ion channels, including INCRUSE ELLIPTA® (umeclidinium) and Dinirixin. His past work has predominantly utilised functional ex vivo tissue preparations, electrophysiology, and calcium imaging techniques.
Jerry holds a BSc in Biomedical Engineering from Drexel University.
Kevin is responsible for delivering preclinical validation in models for respiratory indications. He draws upon standard as well as innovative measurement tools to assess physiological end points and incorporates them into a closed loop design to optimise treatment parameters with the goal of providing a compelling preclinical demonstration.
Prior to joining Galvani Bioelectronics, Kevin led a lead-optimisation program at GSK developing small molecule sodium channel blockers for cough and other respiratory indications.
Kevin earned a PhD in physiology at the University of Kentucky and completed post-doctoral training at Johns Hopkins University, where he made contributions to the knowledge of airway sensory neurobiology.
Kristen leads the U.S. Translational Development team of preclinical scientific content experts generating pre-clinical data and supporting clinical study implementation. With extensive experience in Alliance Management and a CA-AM certification, Kristen’s responsibility also include maintaining key relationships with external partners ensuring best practice and synergies across Galvani to deliver value through partnerships.
Prior to joining the Galvani team, Kristen was with GSK for over 20 years in various roles including Worldwide Business Development , Finance, and Marketing. Kristen holds an MBA from Temple University, and a B.S. in Finance from Drexel University.
Lynsay is Galvani’s Operations Associate, and has over 12 years of experience working in the pharmaceutical industry. Together with Clare De Vere, Lynsay provides administrative support to the Galvani Bioelectronics team.
Before joining Galvani Bioelectronics in 2016, Lynsay worked in the sports development sector for a County Sports Partnership and also for the NHS.
Margriet is Director Immunomodulation and Clinical Science Lead in the Clinical Development team. As such she is mainly focusing on the development of neuromodulation strategies for the treatment of (chronic) inflammatory diseases. Her main tasks are to participate in the design and execution of the clinical development strategy and is responsible for the execution of Galvani’s first clinical study. She lead’s and participates in the data review and analysis of the trial results in close collaboration with the Clinical Operations team. She provides expert scientific input to clinical trial documents and the program regulatory dossier and lead or assist with Competent Authority and Ethics Committee/IRB submissions together with the Regulatory team. In addition, she supervises R&D involving ex- and in vivo research delivering proof-of-concept studies on the target nerve performed in collaborative research projects with several universities in Europe.
Margriet holds a PhD in Biochemistry which she obtained at the university in Utrecht (The Netherlands). Previously she was working as COO at Arthrogen (Amsterdam, The Netherlands), a small biotech company developing gene therapy for arthritis. Holding also a position as University Teacher at the division of Clinical Immunology & Rheumatology (Academic Medical Centre (AMC)/University of Amsterdam) she was supervising the research-lines focusing on neuro-inflammationn and gene therapy in rheumatoid arthritis. Currently she holds a position as University Teacher at the Tytgat Institute (AMC) and contributes to the development of neuromodulation for the treatment of inflammatory bowel disease. She is author of over 60 peer-reviewed publications.
After receiving a PhD from the University of Western Australia, Mike successfully completed a Post-Doctoral Fellowship at the Johns Hopkins University where he was trained in multiple neurophysiology techniques.
Mike has established several neurophysiology labs and has lead multiple research projects focused on the sensory and motor innervation of the respiratory system. For the last 10 years, Mike has worked at GSK, initially within Respiratory Drug discovery, but more recently as part of Galvani Bioelectronics.
Mina is responsible for intellectual property (IP) activities for Galvani Bioelectronics. As a UK and European qualified patent attorney, she works closely with the R&D team and the business to capture arising IP, build and manage the IP portfolio. She also evaluates potential IP risks or opportunities and advises the business with strategies to address them.
Prior to joining Galvani Bioelectronics, Mina was in private practice at two leading IP firms, having entered the IP profession in 2011. Coming from an engineering background, her practice had previously been more engineering and computing focused. Mina enjoys working with the complex blend of engineering and biology that Galvani Bioelectronics brings together.
Morten is a director in the development of the bioelectronics devices in the Galvani Bioelectronics team. He draws on experience from several development projects of active medical devices for both stimulation and sensing applications including devices for pain management, paralysis and prosthetic control. Morten’s responsibility is on overall direction of the development projects at Galvani Bioelectronics, with specific focus on user requirements, surgical procedures and instrumentation.
Prior to joining GKS’s Bioelectronics group, Morten spent nearly 15 years working on medical devices at the Alfred Mann Foundation and Bioness in California. He received his PhD in Biomedical and Electronic Engineering from Aalborg University, Denmark.
Paul is Director for Neural Interface Development. In this role he oversees the research and development of Galvani’s portfolio of implantable neurostimulation leads.
Paul has over 10 years of experience in neuromodulation, across several countries. These include the development of a retinal neuroprosthetic to restore sight to the blind as part of the Bionic Vision Australia project (UNSW, Australia), and Medtronic, where he supported and managed Deep Brain Stimulation across Australia and New Zealand.
Phil is Manager of Clinical Translation in the Clinical Development group. Responsibilities include developing translational biomarker strategies to define mechanisms of action and therapeutic response in our clinical trials. Prior to this he was Disease Biology manager, leading multiple projects with our academic collaborators, to demonstrate effects of neuromodulation on defined neural circuits in differing disease conditions.
Phil has extensive non-clinical and clinical experience across multiple therapeutic areas. He joined GSK in 2007, working in Safety Pharmacology with an in vivo cardiovascular and translational focus, followed by a position in Safety Evaluation & Risk Management in the Global Clinical Safety & Pharmacovigilance group. He moved to Pfizer as Non-Clinical Drug Safety Lead for the Neuroscience & Pain Research Unit, before joining Galvani Bioelectronics in 2016. Phil gained a PhD in Physiology & Pharmacology at the University of Strathclyde, followed by a post-doctoral position at the University of Edinburgh in the Centre for Cardiovascular Sciences.
Rizwan is Director of Product Development for Galvani’s first-generation neuromodulation system. From 2016 to mid 2019 he led Galvani’s Technology R&D Innovation Base to unlock new product potential in various areas of neuromodulation devices. He joined GSK in 2016 prior to the formation of the GSK/Verily Lifesciences JV.
Rizwan held a tenured Associate Professorship in the Department of Electrical and Computer Engineering at the University of Florida where he taught and researched Analog and Mixed-Signal Integrated Circuits. He was also Research Scientist at Nvidia developing high-performance GPUs, and Chief Science Officer and co-founder of eTectbio, a biomedical start-up with in-vivo signaling technologies for medication compliance monitoring. Rizwan received his PhD from North Carolina State University in 2004. He has authored or coauthored more than 100 refereed technical abstracts and papers, was the recipient of the National Science Foundation (NSF) Early Career Development Award, the University of Florida Inventor Recognition Award and the Microwave Magazine Best Paper Award.
Bob supports Galvani’s Translational Science programs. Using his 30 years of animal research experience, he ensures that the team has the right animal and surgical models for establishing treatment parameters and generating preclinical evidence of treatment and device safety.
He obtained a Doctor of Veterinary medicine from Colorado State University and a PhD in Cardiovascular physiology from Michigan State University. He also completed a residency in veterinary surgery at Purdue and a fellowship in laboratory animal medicine. Bob spent over 23 years in small molecule drug discovery and safety development animal models, directing surgical support programs, and establishing ultrasound and non-invasive imagine as a research tool supporting the evaluation of drug safety and efficacy.
Santosh M. Baby
Santhosh joined Galvani Bioelectronics as a scientific investigator with translation sciences in treatment discovery group. He is involved in exploring and validating novel bioelectronic neuromodulatory therapeutic approach in large animal models for unmet medical needs and/or replacing the existing complex pharmacological approaches.
Santhosh received his Ph.D. in Neuroendocrinology from India and followed by postdoctoral position at University of Pennsylvania School of Medicine, where he engaged in understanding molecular mechanisms of oxygen sensing in the carotid chemoreceptor cells and developed research tools for understanding the respiratory phenotype of Duchenne muscular dystrophy (DMD) animal model.
Prior to joining Galvani Bioelectronics in 2017, Santhosh was with Galleon Pharmaceuticals, where he was engaged in identifying the carotid body chemoreceptor modulators that can selectively modulate the upper airway respiratory muscle activities to treat respiratory disorders.
Sarah holds a scientific investigator role within Disease Biology at Galvani Bioelectronics. Here she explores, refines and validates current avenues for pre-clinical neuromodulation. Previously Sarah was part of the Bioelectronics R&D Unit at GSK working as a postdoctoral researcher. She holds a strong background in integrative electrophysiology and an understanding of central and peripheral neuronal control of autonomic function.
Sarah received her PhD in Advanced Medicine from Macquarie University, Sydney, Australia. Here, she focused on prefrontal cortex control of cardiorespiratory and thermoregulatory function under the scope of methamphetamine abuse and mental health disorders.
Sarah is the Legal and Transactions Director of Galvani Bioelectronics. As the lead contracting attorney, Sarah is responsible for providing legal advice and transactional support to the business. She has a key role in managing legal risks facing the company as well as developing capabilities to support efforts to bring products to commercialisation.
Before joining Galvani Bioelectronics, Sarah was in private legal practice at Slaughter and May, specialising in intellectual property, technology and commercial law. In this role, Sarah was one of the lead lawyers who worked on the formation of Galvani Bioelectronics.
Sarah completed the Law Tripos at the University of Cambridge (Christ’s College), earning a Bachelor of Arts with Honours. Following this, she completed the Accelerated Legal Practice Course with Distinction.
Sebastien leads the mechanical design efforts for the neural interface development at Galvani Bioelectronics.
Prior to his work at Galvani Bioelectronics, Sebastien worked in many areas of design engineering, across several countries. These include piezoelectric micro-systems in NOLIAC (Denmark) and Safran Electronics & Defense (France), before moving to implantable medical devices when he joined Sorin/LivaNova (France) to develop pacemaker and defibrillator systems, with specific focus on the leads and interfaces. Sebastien also spent 4 years at Medtronic (Netherlands) to work on the development of thin-film based leads and interfaces for deep brain stimulation.
Sebastien has a Master of Science in Mechanical and Microtechnoloy Engineering from the French National School of Mechanical Engineering and Microtechnology (ENSMM).
Sheridan is a manager within the Clinical Development line, bridging the pre-clinical and clinical space. She leads Galvani’s Indication Expansion Programme, enabling, through matrix management the identification of tractable disease areas, development of robust confidence in rationale and safety, identification of biomarkers, mechanism of action understanding and clinical translation.
Sheridan has over 19 years of drug discovery and development experience, with strong expertise in Physiology, Pharmacology, and Electrophysiology. Sheridan joined Galvani as part of the Discovery Biology team, where she managed multiple external academic collaborations developed to investigate the effects of neuromodulation on defined neural circuits across several disease areas. Prior to joining Galvani, Sheridan worked at Pfizer across various therapeutic areas, including Pain, Sensory Disorders, Genitourinary and Urology, where she held numerous pre-clinical roles from ex vivo model development, early exploratory program lead to ex vivo/in vivo lead on candidate seeking and first-in-human programmes.
Sheridan holds a B.Sc. in Biological Science from the University of Greenwich and a PhD in Neurobiology from Kings College London. Her research focussed on the direct effect of inflammatory mediators on peripheral sensory processing and their role in sensory perception and associated disorders.
Simon is the Lead Biomedical Systems Engineer, supporting the development of the next generation Galvani neuromodulation system.
Prior to joining Galvani in Nov 2017, he was with CareFusion/Becton, Dickinson and Company (BD) as Sr. Systems Engineer for the development of the new medical ventilators.
Simon earned a Ph.D. in Biomedical Engineering from Drexel University, Philadelphia, where his focus was to design a wireless intracranial pressure sensor for the patients with traumatic brain injury. He obtained an M.S. in Biomedical Engineering and B.S. in Electrical Engineering separately both from Beijing Institute of Technology, Beijing, China.
Tariqus brings multi-disciplinary expertise in low-power microchip design, animal research and clinical study to the Bioelectronics team. Prior to joining Galvani Bioelectronics, he spent 10 years in microelectronic laboratories for designing low noise neural recording systems, power-aware real-time biosignal processors and closed-loop neurostimulators. Also, he was a VP of technology of a Toronto-based wearable healthcare start-up, Avertus Inc.
He received his PhD in Electrical Engineering at University of Montréal and MASc in Electrical and Computer Engineering at Concordia University, Montréal. He completed two postdoctoral fellowships, the first at University of Toronto (in vivo research) and the second at Toronto Western Hospital (clinical study). His multi-disciplinary research works published in more than 50 peer-reviewed journals, conferences and book chapters.
Wesley was an early Galvani adoptee, joining Galvani in January 2014 from GSK. Over the years, he has worn many different hats, ranging from EHS, UK safety and quality lead, lab manager and equipment inventory lead, purchasing support, and in-vivo study support.
Wesley current supports the Clinical Translation team as an in-vivo study director, leading disease model characterisation studies while bringing together many different workstream leads across Galvani and GSK to deepen our understanding of such target diseases, identifying potential clinically translatable biomarkers to set us up well for our pre-clinical studies. Here we will determine efficacy of our therapy for new diseases, potentially leading to subsequent Clinical Development.
Yujin is a Neurophysiology Investigator within the Translational Sciences group at Galvani Bioelectronics. Her role is to bridge the gap between pre-clinical, engineering and clinical research through understanding and identification of anatomical locations, stimulation parameters and physiological readouts for nervous system stimulation on peripheral organs using ex vivo and in vivo physiology in large animals.
Prior to joining Galvani, Yujin worked in the field of cardiovascular physiology. She obtained a PhD in Physiology, Anatomy and Genetics at the University of Oxford, followed by a postdoctoral position at King’s College London, where she investigated the mechanisms of cardiac ion transport and electrophysiology in health and disease, and how dysregulation of ion transport affects cardiac electrical signalling, metabolism and myocardial function in rodents.